Live Updates: COVID-19 Cases
  • World 30,480,860
    World
    Confirmed: 30,480,860
    Active: 7,363,727
    Recovered: 22,165,100
    Death: 952,033
  • USA 6,884,280
    USA
    Confirmed: 6,884,280
    Active: 2,525,311
    Recovered: 4,156,590
    Death: 202,379
  • India 5,247,627
    India
    Confirmed: 5,247,627
    Active: 1,019,663
    Recovered: 4,143,247
    Death: 84,717
  • Brazil 4,457,443
    Brazil
    Confirmed: 4,457,443
    Active: 569,330
    Recovered: 3,753,082
    Death: 135,031
  • Russia 1,091,186
    Russia
    Confirmed: 1,091,186
    Active: 170,784
    Recovered: 901,207
    Death: 19,195
  • Peru 750,098
    Peru
    Confirmed: 750,098
    Active: 124,439
    Recovered: 594,513
    Death: 31,146
  • Mexico 684,113
    Mexico
    Confirmed: 684,113
    Active: 123,518
    Recovered: 488,416
    Death: 72,179
  • South Africa 655,572
    South Africa
    Confirmed: 655,572
    Active: 54,497
    Recovered: 585,303
    Death: 15,772
  • Spain 654,637
    Spain
    Confirmed: 654,637
    Active: 624,232
    Recovered: ?
    Death: 30,405
  • Chile 442,827
    Chile
    Confirmed: 442,827
    Active: 14,647
    Recovered: 415,981
    Death: 12,199
  • Iran 416,198
    Iran
    Confirmed: 416,198
    Active: 36,741
    Recovered: 355,505
    Death: 23,952
  • France 415,481
    France
    Confirmed: 415,481
    Active: 293,546
    Recovered: 90,840
    Death: 31,095
  • UK 385,936
    UK
    Confirmed: 385,936
    Active: 344,204
    Recovered: ?
    Death: 41,732
  • Bangladesh 345,805
    Bangladesh
    Confirmed: 345,805
    Active: 88,589
    Recovered: 252,335
    Death: 4,881
  • Saudi Arabia 328,720
    Saudi Arabia
    Confirmed: 328,720
    Active: 15,938
    Recovered: 308,352
    Death: 4,430
  • Pakistan 304,386
    Pakistan
    Confirmed: 304,386
    Active: 6,295
    Recovered: 291,683
    Death: 6,408
  • Turkey 298,039
    Turkey
    Confirmed: 298,039
    Active: 26,979
    Recovered: 263,745
    Death: 7,315
  • Italy 294,932
    Italy
    Confirmed: 294,932
    Active: 42,457
    Recovered: 216,807
    Death: 35,668
  • Germany 270,653
    Germany
    Confirmed: 270,653
    Active: 19,890
    Recovered: 241,300
    Death: 9,463
  • Canada 141,268
    Canada
    Confirmed: 141,268
    Active: 8,764
    Recovered: 123,304
    Death: 9,200
  • Netherlands 90,047
    Netherlands
    Confirmed: 90,047
    Active: 83,774
    Recovered: ?
    Death: 6,273
  • China 85,255
    China
    Confirmed: 85,255
    Active: 165
    Recovered: 80,456
    Death: 4,634
  • Australia 26,861
    Australia
    Confirmed: 26,861
    Active: 2,169
    Recovered: 23,855
    Death: 837
  • S. Korea 22,783
    S. Korea
    Confirmed: 22,783
    Active: 2,635
    Recovered: 19,771
    Death: 377
  • New Zealand 1,809
    New Zealand
    Confirmed: 1,809
    Active: 70
    Recovered: 1,714
    Death: 25

Zydus Cadila launches generic version of Remdesivir at Rs 2,800 per vial in India

Author at TechGenyz India
Remdac

Drug firm Zydus Cadila on Thursday said it has launched a generic version of Remdesivir, used for treating patients suffering from severe COVID-19 symptoms, at Rs 2,800 per 100 mg vial in the Indian market.

Branded as Remdac, the drug is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing.

The company said the drug will be made available across India through the group’s distribution chain reaching out to government and private hospitals treating COVID-19 patients.

Remdac is the most affordable drug as we would like to enable patients to have access to this critical drug in the treatment of COVID-19,” Cadila Healthcare Managing Director Sharvil Patel said.

Through the course of this pandemic, the company’s efforts have been focused on supporting people in this healthcare crisis, whether it is through developing vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests available or exploring new treatment options, he added.

The active pharmaceutical ingredient (API) for the drug has been developed and manufactured at the group’s API manufacturing facilities in Gujarat, Zydus Cadila said.

Complete backward integration makes Remdac the most economical Remdesivir brand in India, it added.

In June this year, Zydus had entered into a non-exclusive agreement with Gilead Sciences to manufacture and sell Remdesivir, the investigational drug, which has been issued an emergency use authorisation by the US Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of COVID-19, the filing said.

Zydus Cadila’s vaccine ZyCov-D is now in phase-II of clinical trials, it added.

Zydus Cadila is the fifth company to have launched its generic version of Remdesivir in India. Hetero Labs, Cipla, Mylan and Jubilant Life Sciences have already launched their generic versions of antiviral drug Remdesivir in the country.

With a record single-day spike of 66,999 cases, India’s COVID-19 tally mounted to 23,96,637 on Thursday, according to the health ministry.

Shares of Cadila Healthcare, the listed entity of the Zydus group settled at Rs 385.90 per scrip on BSE, up 0.16 per cent from its previous close.

Career

Subscribe